Webdisclosure.fr

Search

UCB (EBR:UCB) UCB Media Room: Disposal of own shares

Directive transparence : information réglementée

09/09/2022 20:00
https://mb.cision.com/Public/18595/3628890/b532caec227679a2_800x800ar.png ** Disposal of own shares ------------------------------------------------------------ Brussels (Belgium), 9 September 2022 =E2=80=93 20:00 (CEST) =E2=80=93 Regul= ated information=C2=A0 In accordance with article 8:6 of the Royal Decree executing the Belgian Co= de of Companies and Associations, UCB announces that on 5 September 2022, i= n accordance with the vesting rules under its 2020 and 2021 LTI plan, UCB S= A/NV has delivered for free a total of 742 UCB shares OTC to 4 members of t= he personnel of the Company and its subsidiaries. The highest independent b= id price on Euronext Brussels on 5 September 2022 was =E2=82=AC 69.50. This press release is available on UCB SA/NV=E2=80=99s website via the foll= owing link (https://www.ucb.com/stories-media/Press-Releases) . For further information, contact UCB:=C2=A0 Investor Relations Antje Witte=C2=A0 T +32 2 559 94 14 antje.witte@ucb.com Corporate Communications Laurent Schots=C2=A0 T+32 2 559 92 64 laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 8 600 peopl= e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.8 bi= llion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us = on Twitter: @UCB_news =C2=A0 GenericFile 220909 - Disposals of own shares ENG (https://mb.cision.com/Public/18595/36= 28890/b94f54101d82a991.pdf) GenericFile 220909 - Ali=C3=A9nation d actions propres FR (https://mb.cision.com/Public= /18595/3628890/bb3c15c46205f707.pdf) GenericFile 220909 - Vervreemding van eigen aandelen NL (https://mb.cision.com/Public/1= 8595/3628890/a1673daa923a588f.pdf) ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x115493x1x6868579x2400= 0x6&Email=3Dregnews%40symexglobal.com. UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium